Integrative analysis of the colorectal cancer proteome: potential clinical impact

Expert Review of Proteomics

Volumn 13, Issue 10, 2016, Pages 917-927

  Alnabulsi, Abdo ^a,b   Murray, Graeme I ^a  

^a UNIVERSITY OF ABERDEEN   (United Kingdom)

^b Vertebrate Antibodies ^*  (United Kingdom)

Author keywords

Biomarkers; colorectal cancer; diagnosis; predictive screening; prognosis; proteomics

Indexed keywords

PROTEOME; TUMOR MARKER;

CANCER DIAGNOSIS; CANCER INCIDENCE; CANCER MORTALITY; CANCER PROGNOSIS; CANCER SCREENING; CANCER THERAPY; CLINICAL PRACTICE; COLORECTAL CANCER; COMPUTER ANALYSIS; DISEASE MARKER; GENOMICS; HUMAN; METASTASIS; MOLECULAR PATHOLOGY; NONHUMAN; PRACTICE GUIDELINE; PREDICTION; PROTEIN ANALYSIS; PROTEOMICS; REVIEW; TREATMENT OUTCOME;

EID: 84988476553     PISSN: 14789450     EISSN: 17448387     Source Type: Journal    
DOI: 10.1080/14789450.2016.1233062     Document Type: Review

References (99)

1. R.L.Siegel, K.D.Miller, A.Jemal Cancer statistics, 2015. CA Cancer J Clin. 2015;65:5–29.
2. R.Siegel, D.Naishadham, A.Jemal. Cancer statistics, 2013. CA Cancer J Clin. 2013;63:11–30.
3. C.Coghlin, G.I.Murray. Biomarkers of colorectal cancer:recent advances and future challenges. Proteomics Clin Appl. 2015;9:64–71.
4. N.Pavlidis, G.Pentheroudakis. Cancer of unknown primary site. Lancet. 2012;379:1428–1435.
5. J.Williams, R.Pullan, J.Hill, et al. Management of the malignant colorectal polyp:ACPGBI position statement. Colorectal Dis. 2013;15:1–38.
6. B.J.Elmunzer, R.A.Hayward, P.S.Schoenfeld, et al. Effect of flexible sigmoidoscopy-based screening on incidence and mortality of colorectal cancer:a systematic review and meta-analysis of randomized controlled trials. PLoS Med. 2012;9:e1001352.
7. P.Hewitson, P.Glasziou, E.Watson, et al. Cochrane systematic review of colorectal cancer screening using the fecal occult blood test (hemoccult):an update. Am J Gastroenterol. 2008;103:1541–1549.
8. J.Creeden, F.Junker, S.Vogel-Ziebolz, et al. Serum tests for colorectal cancer screening. Mol Diagn Ther. 2011;15:129–141.
9. M.Blanco-Calvo, A.Concha, A.Figueroa, et al. Colorectal cancer classification and cell heterogeneity:a systems oncology approach. Int J Mol Sci. 2015;16:13610–13632.
10. W.Van Gijn, C.A.Marijnen, I.D.Nagtegaal, et al. Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer:12-year follow-up of the multicentre, randomised controlled TME trial. Lancet Oncol. 2011;12:575–582.
11. E.S.O’Connor, D.Y.Greenblatt, N.K.LoConte, et al. Adjuvant chemotherapy for stage II colon cancer with poor prognostic features. J Clin Oncol. 2011;29:3381–3388.
12. Biomarkers Definitions Working Group. Biomarkers and surrogate endpoints:preferred definitions and conceptual framework. Clin Pharmacol Ther. 2001;69:89–95.
13. D.Cheasley, R.N.Jorissen, S.Liu, et al. Genomic approach to translational studies in colorectal cancer. Transl Cancer Res. 2015;4:235–255.
14. W.G.Feero, A.E.Guttmacher, U.McDermott, et al. Genomics and the continuum of cancer care. N Engl J Med. 2011;364:340–350.
15. N.Kocevar, P.Hudler, R.Komel. The progress of proteomic approaches in searching for cancer biomarkers. N Biotechnol. 2013;30:319–326.
16. K.Bardhan, K.Liu. Epigenetics and colorectal cancer pathogenesis. Cancers. 2013;5:676–713.
17. V.Marx. Biology:the big challenges of big data. Nature. 2013;498:255–260.
18. J.Fan, F.Han, H.Liu. Challenges of big data analysis. Nat Sci Rev. 2014;1:293–314.
19. M.G.Ross, C.Russ, M.Costello, et al. Characterizing and measuring bias in sequence data. Genome Biol. 2013;14:R51.
20. J.Xuan, Y.Yu, T.Qing, et al. Next-generation sequencing in the clinic:promises and challenges. Cancer Lett. 2013;340:284–295.
21. S.R.Dundas, G.I.Murray. Proteomics of bone and soft tissue sarcomas. Current Proteomics. 2012;9:94–102.
22. L.Zhou, K.Wang, Q.Li, et al. Clinical proteomics-driven precision medicine for targeted cancer therapy:current overview and future perspectives. Expert Rev Proteomics. 2016;13:367–381.
23. T.Bonaldi, R.Noberini. Recent advances in mass spectrometry analysis of histone post-translational modifications:potential clinical impact of the PAT-H-MS approach. Expert Rev Proteomics. 2016;13:245–250.
24. K.J.Brown, C.A.Formolo, H.Seol, et al. Advances in the proteomic investigation of the cell secretome. Expert Rev Proteomics. 2012;9:337–345.
25. K.P.Janssen, K.Knez, D.Spasic, et al. Nucleic acids for ultra-sensitive protein detection. Sensors. 2013;13:1353–1384.
26. D.C.Vincenti, G.I.Murray. The proteomics of formalin-fixed wax-embedded tissue. Clin Biochem. 2013;46:546–551.
27. P.Alvarez-Chaver, O.Otero-Estevez, M.Paez de la Cadena, et al. Proteomics for discovery of candidate colorectal cancer biomarkers. World J Gastroenterol. 2014;20:3804–3824.
28. J.A.Gibson, R.D.Odze. Pathology of premalignant colorectal neoplasia. Dig Endosc. 2016;28:312–323.
29. S.R.Cairns, J.H.Scholefield, R.J.Steele, et al. Guidelines for colorectal cancer screening and surveillance in moderate and high risk groups (update from 2002). Gut. 2010;59:666–689.
30. J.Wang, X.Wang, S.Lin, et al. Identification of kininogen-1 as a serum biomarker for the early detection of advanced colorectal adenoma and colorectal cancer. PloS One. 2013;8:e70519.
31. L.Agatea, S.Crotti, E.Ragazzi, et al. Peptide patterns as discriminating biomarkers in plasma of patients with familial adenomatous polyposis. Clin Colorectal Cancer. 2015;published online 2015 Dec19. DOI:10.1016/j.clcc.2015.12.002.
32. J.Choi, H.Liu, D.H.Shin, et al. Proteomic and cytokine plasma biomarkers for predicting progression from colorectal adenoma to carcinoma in human patients. Proteomics. 2013;13:2361–2374.
33. N.Bezawada, M.Song, K.Wu, et al. Urinary PGE-M levels are associated with risk of colorectal adenomas and chemopreventive response to anti-inflammatory drugs. Cancer Prev Res. 2014;7:758–765.• Excellent paper which compared large number of samples collected from prospective cohorts. The paper presented promising urinary-based marker and confirmed the importance of prostaglandin pathway in CRC.
34. R.Eisner, R.Greiner, V.Tso, et al. A machine-learned predictor of colonic polyps based on urinary metabolomics. Biomed Res Int. 2013;2013:303982.
35. D.Besson, A.H.Pavageau, I.Valo, et al. A quantitative proteomic approach of the different stages of colorectal cancer establishes OLFM4 as a new nonmetastatic tumour marker. Mole Cell Proteomics. 2011;10:M111.009712.
36. Y.Qiu, T.H.Patwa, L.Xu, et al. Plasma glycoprotein profiling for colorectal cancer biomarker identification by lectin glycoarray and lectin blot. J Proteome Res. 2008;7:1693–1703.
37. O.Roeise, S.Sivertsen, T.E.Ruud, et al. Studies on components of the contact phase system in patients with advanced gastrointestinal cancer. Cancer. 1990;65:1355–1359.
38. M.E.Duncan, S.M.McAleese, N.A.Booth, et al. A simple enzyme-linked immunosorbent assay (ELISA) for the neuron-specific gamma isozyme of human enolase (NSE) using monoclonal antibodies raised against synthetic peptides corresponding to isozyme sequence differences. J Immunol Methods. 1992;151:227–236.
39. C.Coghlin, G.I.Murray. Progress in the identification of plasma biomarkers of colorectal cancer. Proteomics. 2013;13:2227–2228.
40. M.J.Shrubsole, Q.Cai, W.Wen, et al. Urinary prostaglandin E2 metabolite and risk for colorectal adenoma. Cancer Prev Res. 2012;5:336–342.
41. J.C.Johnson, C.R.Schmidt, M.J.Shrubsole, et al. Urine PGE-M:a metabolite of prostaglandin E2 as a potential biomarker of advanced colorectal neoplasia. Clin Gastroenterol Hepatol. 2006;4:1358–1365.
42. M.Nakanishi, D.C.Montrose, P.Clark, et al. Genetic deletion of mPGES-1 suppresses intestinal tumorigenesis. Cancer Res. 2008;68:3251–3259.
43. K.Colbert Maresso, E.Vilar, E.T.Hawk. Urinary PGE-M in colorectal cancer:predicting more than risk? Cancer Prev Res. 2014;7:969–972.
44. K.W.Kim, K.M.Krajewski, J.P.Jagannathan, et al. Cancer of unknown primary sites:what radiologists need to know and what oncologists want to know. AJR Am J Roentgenol. 2013;200:484–492.
45. N.Pavlidis, H.Khaled, R.Gaafar. A mini review on cancer of unknown primary site:a clinical puzzle for the oncologists. J Adv Res. 2015;6:375–382.
46. A.Dragomir, M.de Wit, C.Johansson, et al. The role of SATB2 as a diagnostic marker for tumours of colorectal origin:results of a pathology-based clinical prospective study. Am J Clin Pathol. 2014;141:630–638.
47. K.Magnusson, M.de Wit, D.J.Brennan, et al. SATB2 in combination with cytokeratin 20 identifies over 95% of all colorectal carcinomas. Am J Surg Pathol. 2011;35:937–948.
48. H.L.McLeod, G.I.Murray. Tumour markers of prognosis in colorectal cancer. Br J Cancer. 1999;79:191–203.
49. N.Snoeren, B.L.Emmink, M.J.Koerkamp, et al. Maspin is a marker for early recurrence in primary stage III and IV colorectal cancer. Br J Cancer. 2013;109:1636–1647.• Excellent paper which used different techniques and followed well-designed approach to identify possible stage specific markers.
50. C.M.Payne, H.Holubec, C.Crowley-Skillicorn, et al. Maspin is a deoxycholate-inducible, anti-apoptotic stress-response protein differentially expressed during colon carcinogenesis. Clin Exp Gastroenterol. 2011;4:239–253.
51. C.L.Han, J.S.Chen, E.C.Chan, et al. An informatics-assisted label-free approach for personalized tissue membrane proteomics:case study on colorectal cancer. Mol Cell Proteomics. 2011;10:M110.003087.• Good paper illustrating interesting method whereby membrane proteome can be analyzed for biomarkers discovery.
52. S.Surinova, L.Radova, M.Choi, et al. Non-invasive prognostic protein biomarker signatures associated with colorectal cancer. EMBO Mol Med. 2015;7:1153–1165.•• Excellent paper illustrating the benefits of using targeted proteomic in plasma proteome analysis. Strong study design was used for the identification and validation of proteins signature.
53. H.T.Tan, W.Wu, Y.Z.Ng, et al. Proteomic analysis of colorectal cancer metastasis:stathmin-1 revealed as a player in cancer cell migration and prognostic marker. J Proteome Res. 2012;11:1433–1445.
54. W.Wu, X.F.Tan, H.T.Tan, et al. Unbiased proteomic and transcript analyses reveal that stathmin-1 silencing inhibits colorectal cancer metastasis and sensitizes to 5-fluorouracil treatment. Mol Cancer Res. 2014;12:1717–1728.
55. S.Ogino, K.Nosho, Y.Baba, et al. A cohort study of STMN1 expression in colorectal cancer:body mass index and prognosis. Am J Gastroenterol. 2009;104:2047–2056.
56. D.O’Dwyer, L.D.Ralton, A.O’Shea, et al. The proteomics of colorectal cancer:identification of a protein signature associated with prognosis. PloS One. 2011;6:e27718.
57. R.S.Mehta, D.Q.Chong, M.Song, et al. Association between plasma levels of macrophage inhibitory cytokine-1 before diagnosis of colorectal cancer and mortality. Gastroenterology. 2015;149:614–622.
58. L.Jankova, O.F.Dent, M.P.Molloy, et al. Reporting in studies of protein biomarkers of prognosis in colorectal cancer in relation to the REMARK guidelines. Proteomics Clin Appl. 2015;9:1078–1086.
59. L.M.McShane, D.G.Altman, W.Sauerbrei, et al. Reporting recommendations for tumour MARKer prognostic studies (REMARK). Br J Cancer. 2005;93:387–391.
60. P.G.Febbo, M.Ladanyi, K.D.Aldape, et al. NCCN task force report:evaluating the clinical utility of tumour markers in oncology. J Natl Compr Canc Netw. 2011;9:S1–32.
61. E.Van Cutsem, B.Nordlinger, A.Cervantes, et al. Advanced colorectal cancer:ESMO clinical practice guidelines for treatment. Ann Oncol. 2010;21:v93–v97.
62. D.J.Sargent, S.Marsoni, G.Monges, et al. Defective mismatch repair as a predictive marker for lack of efficacy of fluorouracil-based adjuvant therapy in colon cancer. J Clin Oncol. 2010;28:3219–3226.
63. D.T.Le, J.N.Uram, H.Wang, et al. PD-1 blockade in tumours with mismatch-repair deficiency. N Engl J Med. 2015;372:2509–2520.
64. P.Martin, S.Noonan, M.P.Mullen, et al. Predicting response to vascular endothelial growth factor inhibitor and chemotherapy in metastatic colorectal cancer. BMC Cancer. 2014;14:887.
65. E.Van Cutsem, C.Köhne, E.Hitre, et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med. 2009;360:1408–1417.
66. S.Torres, I.Garcia-Palmero, M.Herrera, et al. LOXL2 is highly expressed in cancer-associated fibroblasts and associates to poor colon cancer survival. Clin Cancer Res. 2015;21:4892–4902.• The study described the purification and analysis of proteome in colon cancer-associated fibroblast using multiple techniques.
67. R.S.Croner, M.Sevim, M.V.Metodiev, et al. Identification of predictive markers for response to neoadjuvant chemoradiation in rectal carcinomas by proteomic isotope coded protein label (ICPL) analysis. Int J Mol Sci. 2016;17:209.
68. E.T.McKinley, H.Liu, W.H.McDonald, et al. Global phosphotyrosine proteomics identifies PKCδ as a marker of responsiveness to Src inhibition in colorectal cancer. PloS One. 2013;8:e80207.
69. T.Katsila, M.Juliachs, J.Gregori, et al. Circulating pEGFR is a candidate response biomarker of cetuximab therapy in colorectal cancer. Clin Cancer Res. 2014;20:6346–6356.
70. A.M.Baker, D.Bird, J.C.Welti, et al. Lysyl oxidase plays a critical role in endothelial cell stimulation to drive tumour angiogenesis. Cancer Res. 2013;73:583–594.
71. M.Song, X.Zhang, K.Wu, et al. Plasma adiponectin and soluble leptin receptor and risk of colorectal cancer:a prospective study. Cancer Prev Res. 2013;6:875–885.
72. F.Zoratto, L.Rossi, M.Verrico, et al. Focus on genetic and epigenetic events of colorectal cancer pathogenesis:implications for molecular diagnosis. Tumour Biol. 2014;35:6195–6206.
73. H.Chen, S.Werner, S.Tao, et al. Blood autoantibodies against tumour-associated antigens as biomarkers in early detection of colorectal cancer. Cancer Lett. 2014;346:178–187.
74. R.Villar-Vazquez, G.Padilla, M.J.Fernandez-Acenero, et al. Development of a novel multiplex beads-based assay for autoantibody detection for colorectal cancer diagnosis. Proteomics. 2016;16:1280–1290.•• This study developed noninvasive diagnostic assay for different antigens in sera samples. The assay showed strong diagnostic performance and was validated on a large size cohort.
75. H.Chen, S.Werner, J.Butt, et al. Prospective evaluation of 64 serum autoantibodies as biomarkers for early detection of colorectal cancer in a true screening setting. Oncotarget. 2016;published online 2016 Feb19. DOI:10.18632/oncotarget.7500.
76. J.J.Ladd, T.Busald, M.M.Johnson, et al. Increased plasma levels of the APC-interacting protein MAPRE1, LRG1, and IGFBP2 preceding a diagnosis of colorectal cancer in women. Cancer Prev Res. 2012;5:655–664.
77. A.Taguchi, J.H.Rho, Q.Yan, et al. MAPRE1 as a plasma biomarker for early-stage colorectal cancer and adenomas. Cancer Prev Res. 2015;8:1112–1119.
78. Y.Stypula-Cyrus, N.N.Mutyal, M.D.Cruz, et al. End-binding protein 1 (EB1) up-regulation is an early event in colorectal carcinogenesis. FEBS Lett. 2014;588:829–835.
79. S.Surinova, M.Choi, S.Tao, et al. Prediction of colorectal cancer diagnosis based on circulating plasma proteins. EMBO Mol Med. 2015;7:1166–1178.•• Excellent paper which described innovative proteomic approach for biomarker discovery and validation. The study also validated their results by transcriptomic validation on external cohorts.
80. E.J.Kuipers, W.M.Grady, D.Lieberman, et al. Colorectal cancer. Nat Rev Disease Primers. 2015;published online 2015 Nov05. DOI:10.1038/nrdp.2015.65.
81. S.Ogino, A.T.Chan, C.S.Fuchs, et al. Molecular pathological epidemiology of colorectal neoplasia:an emerging transdisciplinary and interdisciplinary field. Gut. 2011;60:397–411.
82. D.Colussi, G.Brandi, F.Bazzoli, et al. Molecular pathways involved in colorectal cancer:implications for disease behaviour and prevention. Int J Mol Sci. 2013;14:16365–16385.
83. S.Ogino, R.Nishihara, T.J.VanderWeele, et al. The role of molecular pathological epidemiology in the study of neoplastic and non-neoplastic diseases in the era of precision medicine. Epidemiology. 2016;27:602–611.
84. S.Ogino, P.Lochhead, A.T.Chan, et al. Molecular pathological epidemiology of epigenetics:emerging integrative science to analyse environment, host, and disease. Mod Pathol. 2013;26:465–484.
85. J.M.Kocarnik, S.Shiovitz, A.I.Phipps. Molecular phenotypes of colorectal cancer and potential clinical applications. Gastroenterol Rep. 2015;3:269–276.
86. S.Ogino, P.T.Campbell, R.Nishihara, et al. Proceedings of the second international molecular pathological epidemiology (MPE) meeting. Cancer Causes Control. 2015;26:959–972.
87. S.S.Hori, S.S.Gambhir. Mathematical model identifies blood biomarker-based early cancer detection strategies and limitations. Sci Transl Med. 2011;3:109ra116.
88. O.Pagel, S.Loroch, A.Sickmann, et al. Current strategies and findings in clinically relevant post-translational modification-specific proteomics. Expert Rev Proteomics. 2015;12:235–253.
89. Y.Hathou. Proteomic methods for biomarker discovery and validation. Are we there yet? Expert Rev Proteomics. 2015;12:329–331.
90. N.Selevsek, C.Y.Chang, L.C.Gillet, et al. Reproducible and consistent quantification of the saccharomyces cerevisiae proteome by SWATH-mass spectrometry. Mol Cell Proteomics. 2015;14:739–749.
91. C.Fredolini, S.Byström, E.Pin, et al. Immunocapture strategies in translational proteomics. Expert Rev Proteomics. 2016;13:83–98.
92. National Research Council Committee on a Framework for developing a new taxonomy of disease. Toward precision medicine:building a knowledge network for biomedical research and a new taxonomy of disease. Washington, DC:National Academies Press (US); 2011.
93. C.Coghlin, G.I.Murray. Progress in the development of protein biomarkers of oesophageal and gastric cancers. Proteomics Clin Appl. 2016;10:532–545.
94. J.P.Ioannidis, M.J.Khoury. Improving validation practices in “omics” research. Science. 2011;334:1230–1232.
95. C.Bielow, G.Mastrobuoni, S.Kempa. Proteomics quality control–a quality control software for MaxQuant results. J Proteome Res. 2016;15:777–787.
96. M.de Wit, R.J.Fijneman, H.M.Verheul, et al. Proteomics in colorectal cancer translational research:biomarker discovery for clinical applications. Clin Biochem. 2013;46:466–479.
97. A.Bradbury, A.Pluckthun. Reproducibility:standardize antibodies used in research. Nature. 2015;518:27–29.
98. G.O’Hurley, E.Sjöstedt, A.Rahman, et al. Garbage in, garbage out:a critical evaluation of strategies used for validation of immunohistochemical biomarkers. Mol Oncol. 2014;8:783–798.
99. C.Schuster, K.Malinowsky, S.Liebmann, et al. Antibody validation by combining immunohistochemistry and protein extraction from formalin‐fixed paraffin‐embedded tissues. Histopathology. 2012;60:E37–E50.